For patients with T2DM and Stage 2 or 3 CKD.
Multicenter Study of the effects of Invokana on renal and cardiovascular outcomes in patients with Diabetes and Diabetic Nephropathy. Assessing the efficacy of Invokana – vs – placebo in reducing end-stage kidney disease. Total study duration is 5.5 years.
To be eligible, must have a documented eGFR of >30 to <90 and a UACR of >300 to <5000 mg/g. Participants will be on maximum tolerated dose of ACE or ARB (can be added/adjusted during screening process).
A1C inclusion is >6.5 to <10.5.
DIABETES TESTING SUPPLIES AND STUDY DRUG PROVIDED AT NO COST.
Most study participants receive stipend for each visit completed, in addition to safety assessments (labs, EKGs, Physician exams, etc).